Success Metrics

Clinical Success Rate
87.5%

Based on 21 completed trials

Completion Rate
88%(21/24)
Active Trials
21(43%)
Results Posted
48%(10 trials)
Terminated
3(6%)

Phase Distribution

Ph phase_1
5
10%
Ph phase_3
2
4%
Ph not_applicable
17
35%
Ph phase_2
18
37%
Ph phase_4
3
6%
Ph early_phase_1
4
8%

Phase Distribution

9

Early Stage

18

Mid Stage

5

Late Stage

Phase Distribution49 total trials
Early Phase 1First-in-human
4(8.2%)
Phase 1Safety & dosage
5(10.2%)
Phase 2Efficacy & side effects
18(36.7%)
Phase 3Large-scale testing
2(4.1%)
Phase 4Post-market surveillance
3(6.1%)
N/ANon-phased studies
17(34.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.0%

21 of 25 finished

Non-Completion Rate

16.0%

4 ended early

Currently Active

21

trials recruiting

Total Trials

49

all time

Status Distribution
Active(23)
Completed(21)
Terminated(4)
Other(1)

Detailed Status

Completed21
Recruiting14
Active, not recruiting7
Terminated3
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
49
Active
21
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (8.2%)
Phase 15 (10.2%)
Phase 218 (36.7%)
Phase 32 (4.1%)
Phase 43 (6.1%)
N/A17 (34.7%)

Trials by Status

terminated36%
withdrawn12%
completed2143%
not_yet_recruiting24%
active_not_recruiting714%
recruiting1429%
unknown12%

Recent Activity

Clinical Trials (49)

Showing 20 of 49 trialsScroll for more
NCT04691986Not Applicable

Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

Active Not Recruiting
NCT06044935Not Applicable

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

Recruiting
NCT05483465Phase 4

The Effect of NAD Supplementation on Brain Vascular Health in Aging

Recruiting
NCT04430517Early Phase 1

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

Active Not Recruiting
NCT06587945Phase 4

Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment

Recruiting
NCT06534944Phase 1

NAD Supplementation and Vascular Health in PAD

Completed
NCT04192136Not Applicable

NAD+ and Exercise in FA

Completed
NCT06032923Phase 1

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Recruiting
NCT05590468Phase 2

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

Active Not Recruiting
NCT05194397Phase 2

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

Recruiting
NCT05023993Not Applicable

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer

Active Not Recruiting
NCT06567717Phase 2

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Recruiting
NCT03568968Phase 3

A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

Completed
NCT05500170Not Applicable

Benefits of Nicotinamide Riboside Upon Cognition and Sleep

Recruiting
NCT04112641Phase 2

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

Active Not Recruiting
NCT05243290Not Applicable

Nicotinamide Riboside Clinical Trial for GWI

Recruiting
NCT07073352Not Applicable

ACEs, SIRT1, and Premature Vascular Aging in Humans

Recruiting
NCT05589766Phase 2

N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease

Completed
NCT06991712Phase 2

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

Recruiting
NCT05546567Not Applicable

NOPARK Open Label Extension Study

Active Not Recruiting

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
49